64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

EJNMMI Research

Table 1 Patient characteristics

Number	Age (y)	Histology	IHC	History of trastuzumab treatment	Number of lesions ( φ <1 cm) detected by MRI/CT/ ⁶⁴ Cu	Number of lesions ( φ >1 cm) detected by MRI/CT/ ⁶⁴ Cu
1	73	IDC-st	3+	Weekly	2/0/0	4/4/4
2	75	IDC-sc	3+	Weekly	0/0/0	1/0/1
3	65	IDC-sc	3+	Weekly	8/0/2	0/0/0
4	54	IDC-sc	3+	Tri-weekly	3/0/1	1/1/1
5	61	IDC-sc	3+	Weekly	0/0/0	1/1/1

y, years; IDC-st, invasive ductal carcinoma-solid tubular; IDC-sc, invasive ductal carcinoma-scirrhous; ⁶⁴Cu, ⁶⁴Cu-DOTA-trastuzumab PET; Weekly, 2 mg/kg/week; Tri-weekly, 8 mg/kg/3 week.